FindTrial
Sign In

Effect of St. John`s wort on the pharmacokinetics and pharmacodynamics of oral oxycodone: A two-phase double-blind cross-over study in healthy volunteers /Mäkikuisman vaikutus suun kautta annetun oksikodonin farmakokinetiikkaan ja dynamiikkaan: kaksivaiheinen kaksoissokea vaihtovuoroinen tutkimus terveillä koehenkilöillä

Effect of St. John`s wort on the pharmacokinetics and pharmacodynamics of oral oxycodone: A two-phase double-blind cross-over study in healthy volunteers /Mäkikuisman vaikutus suun kautta annetun oksikodonin farmakokinetiikkaan ja dynamiikkaan: kaksivaiheinen kaksoissokea vaihtovuoroinen tutkimus terveillä koehenkilöillä

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
EU CTR
Registry ID
EUCTR2007-006135-32-FI
Enrollment
Unknown
Registered
2007-12-28
Start date
2008-01-16
Completion date
Unknown
Last updated
2012-03-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Drug interaction study

Interventions

Trade Name: Oxynorm Product Name: Oxynorm Pharmaceutical Form: Capsule* INN or Proposed INN: OXYCODONE HYDROCHLORIDE CAS Number: 124903 Concentration unit: mg milligram(s) Trade Name: Jarsin® 300 mg

Sponsors

Klaus Tapio Olkkola
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Healthy, 18-40 years, nonsmoking, without chronic diseases or medication Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) F.1.3.1 Number of subjects for this age range

Exclusion criteria

Exclusion criteria: Medication, chronic diseases, abnormal laboratory tests, abuse problems

Design outcomes

Primary

MeasureTime frame
Main Objective: Interaction study;Secondary Objective: ;Primary end point(s): 48 h from test medication—

Countries

Finland

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026